Market Reports

A natural remedy for brain metastasis

Milk thistle extract might be a promising complementary treatment for cancer patients, reports Andrea Zangara, Scientific Marketing Manager, Euromed

The Manufacturing Chemist outsourcing roundtable: part II

Having talked about upcoming trends, potential growth and in-demand services in Part I, I open the second session by asking the panellists whether they’ll be investing in any particular aspects of their businesses during the next 12 months

A matter of material choice

Dr Kevin Robinson recently caught up with DuPont’s Eric Schmohl, Global Marketing Manager for Tyvek Pharmaceutical Packaging, and Jean-François Teneul, Global Life Sciences Market Leader of Tyvek Protective Apparel, to discuss the importance of protecting both people and product during aseptic fill-&-finish processes

Meeting the global demand for high quality pharmaceutical packaging

Amidst a flurry of recent announcements at the recent DCAT Week in New York, Dr Kevin Robinson sat down with Dr Frank Heinricht, Chairman of the Management Board of SCHOTT AG, to discover how the company is addressing issues in the pharmaceutical value chain, from glass tubing to packaging and the application of artificial intelligence

Continuous manufacturing: making it real

Industry pioneers GEA, Siemens and Perceptive Engineering recently hosted the inaugural Reality of Continuous Pharmaceutical Manufacturing conference in Durham, UK, to examine the current status of going conti and present real-life applications to an international audience. Dr Kevin Robinson reports

Global serialisation: Russian track and trace readiness

Christoph Krähenbühl, Senior Director of Excellis Europe, explains the challenge that the new Russian traceability regulations present to the pharma industry and how all participants in the supply chain must properly prepare to ensure that they become compliant within this new environment

Backend, baffling and buzzing: blockchain

Marco Mohwinckel, healthcare executive and adviser, takes a closer look at the invisible backend technology that has been touted as a revolution

Digitalisation in specialty chemicals and pharmaceuticals

Paige Marie Morse, Industry Director, AspenTech talks to Dr Kevin Robinson about accelerating innovation and optimising the value chain with digital technologies

Supporting precision with precision

As biologics steadily grow in pipeline development and commercialisation, they inherently require precise and meticulous support to ensure effective delivery to the patient

The economic advantages of continuous flow chemistry

Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit

The modularisation of chemical API synthesis

The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers

Rare diseases: understanding the patient journey

In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

A new paradigm in vaccines and cancer treatments

Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more

Fuelling pharma’s innovation engines

Wishing to assess the current state of Alcami’s target market, Dr Kevin Robinson recently sat down with President and CEO, Dr Stephan Kutzer, to discuss its health, innovation and future aspirations

Broad stripes, bright stars and a thriving pharmaceutical industry: part I

According to one of Stephen Sondheim’s most well-known lyrics, “I like to be in America! OK by me in America!” But, given the geography, politics, population, regulation and funding that are unique to the United States, Dr Kevin Robinson looked west to the Land of the Free to find out how the pharmaceutical industry is faring amongst all the milk and honey

The hidden risk of contamination

Pharmaceutical companies may be unwittingly putting production processes at risk of contamination by fitting pumps with mechanical seals that fail to comply with industry regulations, says John Smiddy, European Sales and Technical Support Director for AESSEAL

A revolutionary method of liquid flow measurement

Pharmaceutical supplier opts for innovative hygienic flowmeter

Next-generation safety testing

In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable

Developments and the future of pharmaceutical packaging

With the global primary packaging market in the pharmaceutical sector expected to experience remarkable growth during the next few years, Dr Kevin Robinson asked a number of industry experts to comment on the hurdles, drivers and emerging trends that are influencing how drugs are formulated, packaged and delivered

Is the production of biologic drugs ready for an overhaul?

Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson

Leaders of transformation

Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development

Continuous manufacturing: the facts and the future

Many companies talk about continuous manufacturing (CM), but few speak with the experience of actually implementing a continuous process line. Dr Kevin Robinson spoke to GEA’s Richard Steiner to find out why

Looking back on 2018 and making predictions for 2019

As the global pharmaceutical industry transitions from the knowns of 2018 into the unknowns of 2019, Dr Kevin Robinson caught up with some of the key players in the market to assess the year that was and the 12 months to come in terms of upcoming trends and developments

Serialisation is not enough

A global technology leader in supply chain security, Systech’s revolutionary solution provides authentic, safe and connected products throughout the pharmaceutical supply chain. Dr Kevin Robinson recently caught up with CEO Ara Ohanian to find out more

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Building a beta-lactam powerhouse: Gaelic’s strategic leap with Athlone In December 2025, Gaelic Laboratories, a world-class manufacturer of beta-lactam (penicillin) products, acquired Athlone Laboratories, another leading developer and supplier of oral dose beta-lactams
  2. From data to decisions: applying criticality and failure probability in process risk mitigation This article presents an exploration of how structured, data-based methods enhance quality control, optimise specifications and improve process robustness throughout the product lifecycle
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain
  4. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Stop reviewing good data: review‑by‑exception for chromatography QC Labs spend hours confirming routine chromatograms while real risks hide in plain sight; regulators support a better path if data are captured and surfaced correctly, notes George Van Den Driessche, Data Science Product Manager at TetraScience

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all